The Medical Advisor

Medically & Financially Reviewed by: Dr. Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: September 2026 Quick Answer Merck & Co. remains the world's top cancer drug company by 2025 oncology revenue (~$35.4 billion, driven overwhelmingly by Keytruda) , followed by Roche (~$29–30 billion), AstraZeneca ($25.6 billion), Johnson & Johnson ($25.4 billion), and Bristol Myers Squibb (~$25.0 billion). Global oncology drug spending topped an estimated $291 billion in 2025 and is projected to reach roughly $467 billion by 2030 (IQVIA Institute), making cancer treatment the single largest therapeutic category in pharmaceuticals. The competitive picture keeps shifting: Merck's Keytruda faces a 2028 patent cliff, BMS's Revlimid has already lost roughly half its sales to generics, and a wave of Chinese-originated antibody-drug conjugates and PD-1×VEGF bispecifics is reshaping pipelines industry-wide. The oncology drug market looks nothing like it...

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Last Updated: August 2026 Quick Answer:  Cancer treatment is moving from a one-size-fits-all model toward increasingly biomarker-driven, immune-based, targeted and combination therapy . The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress ...